Drug
Mobocertinib clinical trials
Also written TAK-788 and AP32788.
- studies test it
- 10
- open now
- 0
- in phase 3
- 1
- first study started
- 2016
How studies write it
Studies that test it under each name
Name
Studies by the year they started
10 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 1
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses mobocertinib is read from its arms, and is right about nine times in ten.
Testing it · 10
- TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsCompletedPhase 3TakedaNCT04129502Written as TAK-788
- A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung CancerActive, not recruitingPhase 1TakedaNCT03807778Written as Mobocertinib
- A Study of TAK-788 in Adults With Non-Small Cell Lung CancerActive, not recruitingPhase 1/2TakedaNCT02716116Written as TAK-788
- Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedPhase 1Millennium Pharmaceuticals, Inc.NCT04051827Written as TAK-788
- A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT03811834Written as Mobocertinib
- A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy KidneysCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT04056455Written as Mobocertinib
- A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic FunctionCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT04056468Written as Mobocertinib
- A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult ParticipantsCompletedPhase 1TakedaNCT04441255Written as TAK-788
- A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT03928327Written as TAK-788
- A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT03482453Written as TAK-788
Given in every arm · 1 — mobocertinib is usual care beside what is tested
Codes
What other systems call mobocertinib · ClinicalTrials.gg INT001780
- MeSH (NLM) C000720862mobocertinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 39HBQ4A67LMOBOCERTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2570736One source FDA
- Wikidata Q105338009mobocertinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C126752MobocertinibOne source FDA
- DrugBank DB16390One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720862 | mobocertinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 39HBQ4A67L | MOBOCERTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2570736 | — | One source FDA |
| Wikidata | Q105338009 | mobocertinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C126752 | Mobocertinib | One source FDA |
| DrugBank | DB16390 | — | One source Wikidata |
Also registered as mobocertinib succinate (UNII 53QIA92ZEE · RxNorm 2570737).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.